Neurones (FR:NRO)
:NRO
Want to see FR:NRO full AI Analyst Report?
Top Page
Neurones
(NRO)
Select Model
Select Model
Rating:69Neutral
Price Target:
€39.00
▼(-7.14% Downside)
Action:DowngradedDate:05/03/26
The score is primarily supported by solid financial performance (steady growth, low leverage, improving returns), but tempered by margin and free-cash-flow volatility. Technicals are mixed to slightly weak with the price below key longer-term moving averages, while valuation is reasonable with a supportive dividend yield.
Positive Factors
Steady revenue growth
Consistent top-line expansion from 2020–2025 shows durable demand for Neurones’ IT services and sustained client engagement. Steady revenue supports scale economics, allows continued investment in capabilities, and underpins medium-term margin and cash generation potential.
Negative Factors
Gross-margin volatility
Large, unexplained gross-margin swings indicate variability in contract mix, pricing or cost recognition. That volatility undermines operating-margin predictability, complicates planning, and may reflect exposure to low-margin contracts or project overruns that could erode sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth
Consistent top-line expansion from 2020–2025 shows durable demand for Neurones’ IT services and sustained client engagement. Steady revenue supports scale economics, allows continued investment in capabilities, and underpins medium-term margin and cash generation potential.
Read all positive factors
Neurones (NRO) vs. iShares MSCI France ETF (EWQ)
Market Cap
€900.16M
Dividend Yield3.07%
Average Volume (3M)6.80K
Price to Earnings (P/E)6.7
Beta (1Y)0.49
Revenue Growth5.78%
EPS Growth-1.04%
CountryFR
Employees6,849
SectorGeneral
Sector StrengthN/A
IndustryInformation Technology Services
Share Statistics
EPS (TTM)2.14
Shares Outstanding24,328,716
10 Day Avg. Volume4,639
30 Day Avg. Volume6,801
Financial Highlights & Ratios
PEG Ratio-14.54
Price to Book (P/B)3.11
Price to Sales (P/S)1.45
P/FCF Ratio17.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.35
Revenue Forecast (FY)€904.35M
Neurones Business Overview & Revenue Model
Company Description
Neurones S.A., an information technology (IT) services company, provides infrastructure, application, and consulting services in France and internationally. Its infrastructure services include infrastructure management, clouds, user support, DevOp...
How the Company Makes Money
Neurones makes money primarily by selling IT services to business customers under two main delivery modes: (1) project-based work and (2) recurring/managed services. Project-based revenue typically comes from consulting and delivery engagements su...
Neurones Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
86
Very Positive
Cash Flow
71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 857.20M | 810.40M | 741.17M | 665.38M | 579.88M |
| Gross Profit | 90.04M | 388.76M | 346.76M | 81.64M | 69.73M |
| EBITDA | 90.32M | 85.92M | 96.63M | 88.72M | 76.23M |
| Net Income | 61.90M | 52.50M | 49.41M | 44.24M | 37.71M |
Balance Sheet | |||||
| Total Assets | 749.03M | 725.69M | 674.25M | 616.22M | 567.82M |
| Cash, Cash Equivalents and Short-Term Investments | 340.78M | 326.49M | 297.76M | 272.06M | 265.17M |
| Total Debt | 36.96M | 42.02M | 43.98M | 35.57M | 35.32M |
| Total Liabilities | 284.16M | 289.52M | 266.34M | 240.63M | 214.90M |
| Stockholders Equity | 399.98M | 378.10M | 354.39M | 330.58M | 311.56M |
Cash Flow | |||||
| Free Cash Flow | 70.33M | 72.34M | 54.09M | 44.33M | 58.10M |
| Operating Cash Flow | 80.77M | 84.38M | 72.08M | 54.94M | 64.68M |
| Investing Cash Flow | -21.16M | -19.69M | -21.57M | -12.26M | -10.62M |
| Financing Cash Flow | -45.11M | -34.48M | -27.06M | -36.08M | -55.42M |
Neurones Technical Analysis
Positive
42.00
Price Trends
35.51
Positive
38.94
Negative
40.14
Negative
Market Momentum
0.50
Negative
68.27
Neutral
82.59
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:NRO, the sentiment is Positive. The current price of 42 is above the 20-day moving average (MA) of 35.60, above the 50-day MA of 35.51, and above the 200-day MA of 40.14, indicating a neutral trend. The MACD of 0.50 indicates Negative momentum. The RSI at 68.27 is Neutral, neither overbought nor oversold. The STOCH value of 82.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:NRO.
Neurones Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | €1.08B | 9.75 | 12.87% | 0.84% | 7.00% | 20.56% | |
69 Neutral | €900.16M | 6.68 | 14.08% | 3.07% | 5.78% | -1.04% | |
66 Neutral | €2.80B | 4.87 | 14.39% | 3.03% | -2.23% | 20.83% | |
64 Neutral | €17.54B | 6.85 | 10.95% | 2.35% | 1.67% | -3.83% | |
57 Neutral | €2.14B | 26.28 | 6.98% | 2.08% | -1.07% | -42.78% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
41 Neutral | €731.54M | -0.36 | 319.82% | ― | -16.46% | 93.72% |
* General Sector Average
FR:NRO
Neurones
36.90
-9.09
-19.77%
FR:ATE
ALTEN SA
60.85
-13.89
-18.59%
FR:ATO
Atos SE
35.70
-6.30
-15.00%
FR:CAP
Capgemini SE
99.20
-53.19
-34.90%
FR:SOP
Sopra Steria
134.00
-55.08
-29.13%
FR:WAVE
Wavestone
44.40
-7.87
-15.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.